Chinese Public Healthcare Insurance Official Defends Steep Drug Price Cuts

 
• By Dexter Jie Yan
  
Generate a summary of this article
Listen to this article
Beta

China’s National Healthcare Security Administration (NHSA) seems determined to require pharma firms to comply with the agency’s request to cap the prices of innovative drugs, according to a senior official directly involved in annual price negotiations.

NHSA spending on novel drugs
China's NHSA expects drug makers to have a rough estimate of discounts needed for NRDL inclusion • Source: Shutterstock

In the run-up to China’s annual drug price talks, scheduled for November in an update to the National Reimbursement Drug List (NRDL), a senior official at the National Healthcare Security Administration (NHSA) made a rare public appearance to defend the agency’s tough price-cutting stance, which could dampen pharma companies’ hopes of negotiating a premium for their innovative drugs.

The NHSA, which oversees the negotiation process, expects all drug makers to have a rough set of estimates on how...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

Coping Strategies For China Industry Amid BIOSECURE Overhang

 
• By Xu Hu

With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

China Pilots Scheme To Halve IND Review Time For Innovative Drugs

 
• By Dexter Jie Yan

China’s top drug regulator is implementing a pilot program offering shorter review times for IND applications to improve the quality and efficiency of clinical studies and stimulate the country’s innovative drug sector.

$14m Handout Anyone? Shanghai Offers Raft Of New Biopharma Incentives

 
• By Brian Yang

Shanghai issues a new set of policies and financial incentives designed to support and speed up regulatory and commercial activities in the biopharma sector, in a comprehensive stimulus package for companies based in the major Chinese city.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By Lisa Takagi

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By Vibha Sharma

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.